中华医学杂志
2021年 · 第101卷第15期
中华医学杂志
加强老年人哮喘患者的管理 努力改善疾病预后
半乳甘露聚糖试验诊断重症与危重症流感合并侵袭性肺曲霉病的效能分析
脑小血管病患者皮质下缺血性抑郁的脑皮质形态学研究
经皮冠状动脉介入术后优化药物治疗应用现状及其对预后的影响
支气管热成形术治疗重症哮喘与哮喘慢性阻塞性肺疾病重叠患者的临床疗效及安全性分析
改良后内侧经踇长屈肌外侧入路治疗后Pilon骨折
机器人辅助膀胱后入路根治性前列腺切除术的疗效分析
无创产前检测胎儿染色体拷贝数变异在我国实验室的应用情况分析
增龄相关性脑小血管病和特发性正常颅压脑积水共病导致的老年人认知和步态功能障碍三例临床分析
床旁高渗盐水造影肺灌注电阻抗断层成像的技术规范与临床应用
真菌性脊柱炎的磁共振成像表现分析
第535例 感觉异常—下肢无力—尿便障碍
胸膜上皮样血管内皮细胞瘤一例
PD-1抑制剂治疗霍奇金淋巴瘤诱发肾病综合征一例
阿尔茨海默病中肠道菌群研究的新进展
支气管热成形术对于有症状的重症哮喘的安全性和有效性
Although asthma patients can be effectively controlled through drug treatment, there are still 5% to 10% of severe asthma patients who are uncontrolled or partially controlled, and are more likely to have recurrent attacks and possibly life-threatening deterioration than mild asthma patients, seriously damaging the quality of life and bringing a heavy economic burden to individuals and society. Bronchial thermoplasty (BT) aims to reduce airway smooth muscle and improve asthma control. To investigate the safety and efficacy of BT in patients with symptomatic severe asthma, the study will use fluticasone (750 mg/d) or an equivalent dose of long-acting beta2Thirty-two adult asthmatic patients who were treated with receptor agonists and other drugs, including prednisone tablets at 30 mg/d or less, but still had symptoms, were randomly divided into BT and control groups, 15 in BT and 17 in control. Following treatment, the subject entered a 16-week steroid stable phase (Week 6 to Week 22), a 14-week steroid discontinuation phase (Week 22 to Week 36) and a 16-week steroid reduction phase (Week 36 to Week 52). The results showed that BT caused a transient aggravation of asthma symptoms. During the treatment period, 7 of 4 subjects in the BT group were hospitalized for developing respiratory symptoms, 3 subjects had 5 hospitalizations after treatment, 2 for segmental atelectasis, and 1 of them had bronchoscopy and sputum plug aspiration. Seventeen control subjects were not hospitalized during the treatment period, and hospitalization rates were similar in both groups after treatment. At week 22, BT subjects showed significant improvements in rescue medication use, first second forced expiratory volume (FEV1) as a function of predicted value (prior to relaxant use), and asthma control questionnaire (ACQ) scores compared to controls [(-22.6 ± 40.1) actuations/7 d vs. (-1.5 ± 11.7) actuations/7 d,P<0.05); (14.9±17.4) % to (-0.94±22.3) %,P=0.04; -1.04 ± 1.03 vs. -0.13 ± 1.00,P=0.02], there were still statistically significant differences in rescue medication use and ACQ score compared to the control group at week 52. Although BT is associated with short-term increases in asthma-related symptoms, preliminary confirmation suggests long-term sustained improvement in asthma control.
本期目次

